Gain reproducible insight into lipid nanoparticle behaviour in solution. Detect instability, optimise formulations and accelerate RNA therapeutic development with Zetasizer.
Improve Lipid Nanoparticle Drug Delivery with Zetasizer Dynamic Light Scattering, MADLS and Zeta Potential Analysis for Confident Particle Characterisation and Formulation Stability.
Lipid nanoparticles (LNPs) have become a cornerstone of modern drug delivery, enabling the successful development of mRNA vaccines, RNA therapeutics and next-generation nucleic acid medicines. Their performance depends on precise control of particle size, size distribution and colloidal stability throughout formulation, manufacturing and storage. Even small variations can influence encapsulation efficiency, biodistribution, cellular uptake and therapeutic efficacy, making reliable characterisation essential.
Many conventional analytical techniques only identify formulation instability after significant changes have occurred. Zetasizer provides earlier insight into particle behaviour, allowing scientists to monitor critical quality attributes throughout development and manufacturing, helping reduce risk while improving confidence in formulation decisions.
Zetasizer helps you stay ahead of instability, giving you the insight needed to optimise lipid nanoparticle drug delivery with confidence.
With Zetasizer you can:
Works with OmniTrust: Malvern Panalytical's compliance solution for the regulated environment
Lipid nanoparticle formulations are highly sensitive to changes in formulation composition, manufacturing parameters and storage conditions. Small variations in particle characteristics can affect encapsulation efficiency, stability and therapeutic performance, creating hidden risks that may only become apparent during later stages of development or commercial production.
These issues often emerge during scale-up, technology transfer or commercial manufacturing, when process deviations become significantly more expensive to correct.
Earlier insight into particle behaviour can make all the difference.
Subtle changes in particle size, surface charge and interaction behaviour can have a significant impact on RNA delivery efficiency, cellular uptake and overall therapeutic performance. These instabilities are often missed during early development and only become apparent under real-world conditions such as scale-up, storage or transport.
Zetasizer is designed to uncover these risks earlier in development.
Using highly sensitive dynamic light scattering and zeta potential analysis, Zetasizer detects even small changes in particle size distribution and surface charge. This enables scientists to identify early-stage aggregation, instability and interaction changes before they impact performance. The result is faster, more informed decision-making and reduced risk of late-stage failure.
Maintaining a consistent lipid nanoparticle size distribution is fundamental to successful drug delivery. Aggregation can alter biodistribution, reduce encapsulation efficiency and compromise therapeutic efficacy. Unfortunately, early-stage aggregation is often difficult to detect using conventional analytical methods, allowing instability to develop unnoticed.
Dynamic Light Scattering enables rapid, highly sensitive particle size analysis, allowing scientists to detect subtle aggregation before it affects formulation performance. Monitoring particle size throughout formulation development, process optimisation and manufacturing helps identify trends early, supporting proactive decision making and reducing development risk.
Adaptive Correlation improves measurement quality when analysing noisy, unstable, highly concentrated or broad particle size distributions. This enables robust characterisation of challenging lipid nanoparticle samples while increasing confidence in analytical results.
With Zetasizer you can:
Earlier aggregation detection enables formulation scientists to optimise manufacturing conditions and maintain the particle consistency required for reliable therapeutic performance.
Stable lipid nanoparticle formulations are essential for maintaining drug efficacy throughout manufacturing, transportation and storage. Minor adjustments to lipid composition, buffer chemistry or processing conditions can significantly influence particle interactions and long-term stability.
Zeta Potential provides valuable insight into particle surface charge, enabling scientists to predict colloidal stability, assess aggregation risk and compare formulation robustness. These measurements help identify formulation stability windows while supporting optimisation of storage conditions and manufacturing processes.
Using quantitative stability measurements throughout development allows researchers to make informed formulation decisions while reducing the need for repeated experimental iterations.
With Zetasizer you can:
Understanding how surface charge influences particle interactions helps development teams design lipid nanoparticle formulations that remain stable throughout their intended shelf life.
Lipid nanoparticles are sensitive to environmental conditions, processing parameters and storage environments. Over time, they may undergo aggregation, structural rearrangement or destabilisation, impacting delivery performance.
These changes often begin with subtle nanoscale shifts that are difficult to detect without sensitive analytical techniques.
Zetasizer uses dynamic light scattering and zeta potential analysis to detect early indicators of instability. This enables researchers to monitor nanoparticle behaviour across formulation and storage conditions and respond before issues become critical.
With Zetasizer, lipid nanoparticle developers can:
✔ Detect early nanoparticle instability and aggregation
✔ Monitor behaviour across temperature and formulation changes
✔ Maintain consistent nanoparticle quality during development
This reduces development risk and supports more reliable therapeutic outcomes.
Automated workflows powered by the Sample Assistant bring greater consistency and control to lipid nanoparticle analysis. By standardising sample handling, measurement and data collection, the system reduces operator variability and ensures that every sample is analysed under the same conditions.
This is particularly important for lipid nanoparticle systems, where small differences in preparation or measurement can lead to significant variation in results. Consistent workflows ensure that subtle changes in particle behaviour are detected reliably.
Designed for high-throughput environments, the Sample Assistant enables efficient screening of multiple formulations while maintaining analytical sensitivity. Dynamic light scattering and zeta potential measurements remain fully robust, while automation improves reproducibility across studies.
By embedding consistency into every stage of analysis, automated workflows support the generation of high-quality data and enable confident comparison of lipid nanoparticle formulations.
Zetasizer combines analytical sensitivity, reproducibility and ease of use to address the complex challenges of lipid nanoparticle development. From early research through formulation optimisation and stability testing, it provides the insight needed to understand nanoparticle behaviour in solution and reduce development risk.
With Zetasizer, you can:
✔ Measure nanoparticle size using high-sensitivity dynamic light scattering
✔ Analyse zeta potential to understand surface charge and predict stability
✔ Detect early-stage aggregation and instability
✔ Characterise nanoparticle behaviour in real formulation conditions
✔ Compare formulation variables including pH, buffers and excipients
✔ Generate highly reproducible data across experiments and users
✔ Enable high-throughput, standardised workflows with the Sample Assistant
✔ Screen multiple formulations efficiently to identify optimal conditions
✔ Reduce the risk of late-stage failure and reformulation
✔ Accelerate lipid nanoparticle development timelines
By delivering reliable, reproducible insight into lipid nanoparticle behaviour, Zetasizer enables scientists to make better decisions earlier, reduce risk and advance RNA therapeutic development with confidence.
Measure protein size and detect aggregation to optimise stability and support biologic drug development.
Characterise nanoparticle size and surface charge to optimise delivery efficiency and stability.
Verify particle size and stability to maintain product quality and regulatory compliance.
Analyse vesicle size and aggregation to support emerging therapeutic applications.
Characterize protein stability, aggregation and molecular behaviour to ensure efficacy and shelf life.
Analyse particle size and stability of antigens and delivery systems for effective vaccine performance.
Measure viral vector size and stability to ensure safe and effective gene delivery.
Understand nanoparticle size and surface properties to control drug release and targeting.
Measure size, zeta potential and concentration using DLS and NTA. Detect instability early and optimise biologics with Zetasizer and NanoSight.
The basics of Dynamic Light Scattering and electrophoretic light scattering will be discussed. I will review the Dynamic Light Scattering acronyms, i.e what is meant by NIBS and MADLS.
ZetaClass is a comprehensive webinar series on dynamic and electrophoretic light scattering where our experts walk you through the basic measuring principles, data interpretation, and tests performed to gauge data quality.
Join us as we unveil the new and expanded Zetasizer range: Zetasizer Advance. Dr Mike Kaszuba will introduce the new range and help you to pinpoint which system best fits your particle characterization requirements.
This webinar discusses some basic fundamentals of light scattering science and also common misconceptions about light scattering methods
In this webinar, you will learn about developing reliable and effective methods for dynamic light scattering (DLS) and electrophoretic light scattering (ELS) measurements using the Zetasizer Advance instrument. The presentation is geared toward users of DLS and ELS instruments who want to deepen their understanding of method development.
This webinar will explore how the Dynamic Light Scattering (DLS) technique, utilized by the Zetasizer Advance series, ensures compliance with United States Pharmacopeia (USP) guidelines, specifically USP 430.
This webinar will discuss each of the sections contained in United States Pharmacopeia (USP) 432 and what it means for users of Malvern Panalytical’s Zetasizer range of instruments who measure zeta potential in their workflow.
Join us to learn how to assess the quality of your data collected on the Zetasizer Advance instrument. Together we will go through real examples of data from particle size measurements that use Dynamic Light Scattering (DLS) and zeta potential measurements obtained with Electrophoretic Light Scattering (ELS) assessing data quality and sharing tips on how to improve confidence in the results.